ABVC BioPharma (ABVC) Fundamental Analysis: Revenue, Earnings & Valuation

8.36 / 10

Outperform

Fundamental rating is Outperform, scoring 8.36. Strengths include high inventory turnover, accounts receivable turnover, interest coverage, and strong Asset‑MV and PB‑ROE. Weaknesses are zero fixed‑asset turnover and negative income‑tax ratio, dragging some metrics.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score3/3

Weight27.84%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value-100.00

Score2/3

Weight1.48%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.58%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-1.57%

1M Return-0.65%

PB-ROE

Value0.65

Score3/3

Weight40.27%

1M Return12.56%

Income tax / Total profit (%)

Value-0.29

Score0/3

Weight-3.56%

1M Return-1.54%

Fixed assets turnover ratio

Value0.00

Score1/3

Weight-2.93%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.77%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-1.73%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight43.55%

1M Return13.09%

Is ABVC undervalued or overvalued?

ABVC scores 8.36/10 on fundamentals and holds a Discounted valuation at present. Backed by its -112.81% ROE, 0.00% net margin, -3.41 P/E ratio, 2.03 P/B ratio, and 7.14% earnings growth, these metrics solidify its Outperform investment rating.